Friday - April 4, 2025
Goodwin Advises BridgeBio Oncology Therapeutics on Combination Agreement with Helix Acquisition to Create Publicly Listed Biotechnology Company
March 03, 2025
BOSTON, Massachusetts, March 3 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:

* * *

Goodwin Advises BridgeBio Oncology Therapeutics on Combination Agreement with Helix Acquisition to Create Publicly Listed Biotechnology Company

The Special Purpose Acquisitions Companies and Life Sciences teams advised TheRas, Inc. doing business as BridgeBio Oncology Therapeutics ("BBOT") in its definitive business combination . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products